Mylan-Nifedipine Extended Release tablets launched in Canada

May 5 2010

Mylan Pharmaceuticals ULC today announces it has launched Mylan-Nifedipine Extended Release tablets in 30 mg strength. Mylan is the only company in Canada to offer this generic alternative to Adalat(R) XL(R). Previously available in 60 mg tablets, the addition of the 30 mg is another example of how generic manufacturers offer patients greater access to high quality products. Mylan-Nifedipine Extended Release is an important antihypertensive for patients suffering from angina and/or hypertension.

Health Canada has declared Mylan-Nifedipine Extended Release tablets bioequivalent to Adalat(R) XL(R). "We take pride in being the first and only company to offer a generic alternative to Adalat(R) XL(R) in Canada," said Dick Guest, President and CEO of Mylan in Canada. "The launch of this unique and difficult to manufacture tablet demonstrates our dedication to providing quality, more affordable medicines to the Canadian market."

Total sales for Adalat(R) XL(R) 30 mg in Canada were approximately $81 million ($CDN) for the 12 months ending December 31, 2009.

The new medicine continues a long line of Mylan products carefully made to treat angina and/or hypertension including Mylan-Amlodipine, Mylan-Ramipril and Mylan-Lisinopril.